Evidence map›Paper›PMID 30814496›Full record

ArticleCell death & disease2019

MTA2-mediated inhibition of PTEN leads to pancreatic ductal adenocarcinoma carcinogenicity.

Wenzhe Si, Xujun Liu, Rui Wei, Yuan Zhang, Yang Zhao, Liyan Cui, Tianpei Hong

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. CircInternational journal of molecular sciences · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Wenzhe SiDepartment of Laboratory Medicine, Peking University Third Hospital, 100191, Beijing, China.
Xujun LiuDepartment of Laboratory Medicine, Peking University Third Hospital, 100191, Beijing, China.
Rui WeiDepartment of Endocrinology and Metabolism, Peking University Third Hospital, 100191, Beijing, China.
Yuan ZhangDepartment of Laboratory Medicine, Peking University Third Hospital, 100191, Beijing, China.
Yang ZhaoDepartment of Laboratory Medicine, Peking University Third Hospital, 100191, Beijing, China.
Liyan CuiDepartment of Laboratory Medicine, Peking University Third Hospital, 100191, Beijing, China. cliyan@163.com.
Tianpei HongDepartment of Laboratory Medicine, Peking University Third Hospital, 100191, Beijing, China. tpho66@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-5744-5129
Peking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastasis-associated protein 2 (MTA2) is a core subunit of the nucleosome remodeling and deacetylating (NuRD) complex and functions by mediating chromatin remodeling and gene silencing. However, its biological actions and clinical significance in pancreatic ductal adenocarcinoma (PDAC) remain elusive. The aim of this study was to explore the function and regulation mechanism of MTA2 in PDAC. As shown in GEO, ICGC, and TCGA databases, a higher expression of MTA2 was noticed in the PDAC tissues than in the normal pancreatic tissues. Moreover, a higher expression level of MTA2 was associated with a shorter overall survival time in these public PDAC databases. We further investigated the underlying mechanisms of these observations by using a chromatin immunoprecipitation (ChIP)-based deep sequencing, luciferase reporter, and quantitative ChIP assays. We identified the repressive binding of MTA2 to the promoter of phosphatase and tensin homolog (PTEN). We also found that Snail recruited MTA2 and HDAC1 to suppress PTEN expression. Ectopic expression and knockdown of MTA2 were performed to evaluate the effects of this gene on PDAC cell proliferation, migration, and invasion. Using CCK-8, colony formation and transwell assays, and a xenograft tumor model, we revealed that MTA2 promoted PDAC cell proliferation, migration, and invasion in vitro and PDAC tumor growth in vivo by downregulation of PTEN. In benzyl isothiocyanate (BITC)-treated MIA Paca-2 cells and PANC-1 cells, MTA2 level decreased in a dose- and time-dependent manner with concomitant upregulation of PTEN level and downregulation of phosphorylated PI3K and AKT levels, providing evidence of the involvement of MTA2 and PTEN in the regulation of the PI3K/AKT pathway in BITC-mediated PDAC suppression. Collectively, these findings uncover a novel role for MTA2 in the regulation of PDAC progression and help to elucidate the mechanisms involved in this process.

Indexed as

AnimalsCarcinogenesisCarcinoma, Pancreatic DuctalCell Line, TumorDown-RegulationHeterograftsHistone DeacetylasesHumansMi-2 Nucleosome Remodeling and Deacetylase ComplexMiceMice, Inbred BALB CMice, NudePancreatic NeoplasmsPrognosisPTEN PhosphohydrolaseRepressor ProteinsHistone DeacetylasesMi-2 Nucleosome Remodeling and Deacetylase ComplexMTA2 protein, humanPTEN PhosphohydrolasePTEN protein, humanRepressor ProteinsSnail Family Transcription Factors

Identifiers

PMID30814496
PMCPMC6393561
OpenAlexW2916783608

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.